相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effect of CYP2C19*2 and*17 Genetic Variants on Platelet Response to Clopidogrel and Prasugrel Maintenance Dose and Relation to Bleeding Complications
Charlotte Grosdidier et al.
AMERICAN JOURNAL OF CARDIOLOGY (2013)
Clopidogrel variability: role of plasma protein binding alterations
Shobana Ganesan et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Exploring the Ticagrelor-Statin Interplay in the PLATO Trial
James J. DiNicolantonio et al.
CARDIOLOGY (2013)
Randomized Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients With Diabetes
Dimitrios Alexopoulos et al.
DIABETES CARE (2013)
Comparison of Prasugrel and Ticagrelor Loading Doses in ST-Segment Elevation Myocardial Infarction Patients RAPID (Rapid Activity of Platelet Inhibitor Drugs) Primary PCI Study
Guido Parodi et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Ticagrelor Enhances Adenosine-Induced Coronary Vasodilatory Responses in Humans
Ann Wittfeldt et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms (CYP2C19, ABCB1, PON1), Noncompliance, Diet, Smoking, Co-Medications (Including Proton Pump Inhibitors), and Pre-Existent Variability in Platelet Function
Andrew L. Frelinger et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Clopidogrel and Prasugrel The PARADOX Study
Paul A. Gurbel et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Effects of cangrelor in coronary artery disease patients with and without diabetes mellitus: an in vitro pharmacodynamic investigation
Jose L. Ferreiro et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2013)
Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Ticagrelor in Clopidogrel-Resistant Patients Undergoing Maintenance Hemodialysis
Dimitrios Alexopoulos et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2012)
Roles of Purinergic Receptor P2Y, G Protein-Coupled 12 in the Development of Atherosclerosis in Apolipoprotein E-Deficient Mice
Ding Li et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2012)
Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and a History of Stroke or Transient Ischemic Attack
Stefan K. James et al.
CIRCULATION (2012)
Randomized Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients with ST-Segment-Elevation Myocardial Infarction
Dimitrios Alexopoulos et al.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS (2012)
Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile of the Oral Antiplatelet Agent Ticagrelor
Renli Teng
CLINICAL PHARMACOKINETICS (2012)
Comparative Pharmacokinetics and Pharmacodynamics of Platelet Adenosine Diphosphate Receptor Antagonists and their Clinical Implications
Christopher N. Floyd et al.
CLINICAL PHARMACOKINETICS (2012)
Clopidogrel: A Case for Indication-Specific Pharmacogenetics
J. A. Johnson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Ticagrelor: Oral Reversible P2Y12 Receptor Antagonist for the Management of Acute Coronary Syndromes
Judy W. M. Cheng
CLINICAL THERAPEUTICS (2012)
Antiplatelet therapy in patients with ST-elevation myocardial infarction undergoing myocardial revascularisation: beyond clopidogrel
J. Wouter Jukema et al.
CURRENT MEDICAL RESEARCH AND OPINION (2012)
High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study
Johanne Silvain et al.
EUROPEAN HEART JOURNAL (2012)
Statin drug interactions and related adverse reactions
Stefano Bellosta et al.
EXPERT OPINION ON DRUG SAFETY (2012)
Pharmacokinetic basis of the antiplatelet action of prasugrel
Karsten Schroer et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2012)
Association of Clopidogrel Pretreatment With Mortality, Cardiovascular Events, and Major Bleeding Among Patients Undergoing Percutaneous Coronary Intervention A Systematic Review and Meta-analysis
Anne Bellemain-Appaix et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Bridging Antiplatelet Therapy With Cangrelor in Patients Undergoing Cardiac Surgery A Randomized Controlled Trial
Dominick J. Angiolillo et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Pharmacokinetics, Pharmacodynamics, and Safety of Ticagrelor in Volunteers With Severe Renal Impairment
Kathleen Butler et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Combined clopidogrel and proton pump inhibitor therapy is associated with higher cardiovascular event rates after percutaneous coronary intervention: a report from the BASKET trial
T. Burkard et al.
JOURNAL OF INTERNAL MEDICINE (2012)
Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization
Matthew T. Roe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Stroke and Bleeding in Atrial Fibrillation with Chronic Kidney Disease
Jonas Bjerring Olesen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
P2Y12 receptors in platelets and other hematopoietic and non-hematopoietic cells
Christian Gachet
PURINERGIC SIGNALLING (2012)
Prasugrel inhibits platelet-leukocyte interaction and reduces inflammatory markers in a model of endotoxic shock in the mouse
Licia Totani et al.
THROMBOSIS AND HAEMOSTASIS (2012)
Comparison of Differential Expression of P2Y12 Receptor in Culprit Coronary Plaques in Patients With Acute Myocardial Infarction Versus Stable Angina Pectoris
Cheol Whan Lee et al.
AMERICAN JOURNAL OF CARDIOLOGY (2011)
Novel Role of Platelets in Mediating Inflammatory Responses and Ventricular Rupture or Remodeling Following Myocardial Infarction
Yang Liu et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2011)
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions
Glenn N. Levine et al.
CIRCULATION (2011)
Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo-Controlled, Crossover Comparison Studies
D. J. Angiolillo et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes
Giuseppe Biondi-Zoccai et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2011)
Impact of Bleeding on Mortality After Percutaneous Coronary Intervention Results From a Patient-Level Pooled Analysis of the REPLACE-2 (Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events), ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy), and HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trials
Roxana Mehran et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2011)
CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular Events A Systematic Review and Meta-analysis
Michael V. Holmes et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Selective Blockade of P2Y12 Receptors by Prasugrel Inhibits Myocardial Infarction Induced by Thrombotic Coronary Artery Occlusion in Rats
Atsuhiro Sugidachi et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2011)
Safety and Efficacy of Antiplatelet and Antithrombotic Therapy in Acute Coronary Syndrome Patients With Chronic Kidney Disease
Sukhdeep S. Basra et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2011)
Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery Results From the PLATO (Platelet Inhibition and Patient Outcomes) Trial
Claes Held et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2011)
Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity
D. Alexopoulos et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2011)
ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONIST CLOPIDOGREL SULFATE ATTENUATES LPS-INDUCED SYSTEMIC INFLAMMATION IN A RAT MODEL
Satoshi Hagiwara et al.
SHOCK (2011)
Adenosine Diphosphate Receptor P2Y12-Mediated Migration of Host Smooth Muscle-Like Cells and Leukocytes in the Development of Transplant Arteriosclerosis
Kosuke Harada et al.
TRANSPLANTATION (2011)
Prasugrel vs. Ticagrelor in acute coronary syndromes: Which one to choose?
Hannes F. Alber et al.
WIENER KLINISCHE WOCHENSCHRIFT (2011)
Beyond Aspirin and Clopidogrel: Is There a Need for Additional Antiplatelet Therapy in ACS?
Lawrence Rajan et al.
Current Cardiology Reports (2011)
Thienopyridine-Associated Drug-Drug Interactions: Pharmacologic Mechanisms and Clinical Relevance
Jean-Sébastien Hulot et al.
Current Cardiology Reports (2011)
Signalling and pharmacological properties of the P2Y14 receptor
T. K. Harden et al.
ACTA PHYSIOLOGICA (2010)
Regulation of Functionally Active P2Y12 ADP Receptors by Thrombin in Human Smooth Muscle Cells and the Presence of P2Y12 in Carotid Artery Lesions
Bernhard H. Rauch et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
Role of phosphoinositide 3-kinase β in platelet aggregation and thromboxane A2 generation mediated by Gi signalling pathways
Analia Garcia et al.
BIOCHEMICAL JOURNAL (2010)
Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases
Jolanta M. Siller-Matula et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function Results From the Platelet Inhibition and Patient Outcomes (PLATO) Trial
Stefan James et al.
CIRCULATION (2010)
Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement
Dirk Sibbing et al.
CIRCULATION (2010)
Adding Cilostazol to Dual Antiplatelet Therapy Achieves Greater Platelet Inhibition than High Maintenance Dose Clopidogrel in Patients With Acute Myocardial Infarction Results of the Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With AMI (ACCEL-AMI) Study
Young-Hoon Jeong et al.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS (2010)
Changes in Inflammatory Biomarkers in Patients Treated With Ticagrelor or Clopidogrel
Steen Husted et al.
CLINICAL CARDIOLOGY (2010)
Effect of Intrinsic and Extrinsic Factors on the Clinical Pharmacokinetics and Pharmacodynamics of Prasugrel
David S. Small et al.
CLINICAL PHARMACOKINETICS (2010)
Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite
Miho Kazui et al.
DRUG METABOLISM AND DISPOSITION (2010)
Absorption, Distribution, Metabolism, and Excretion of Ticagrelor in Healthy Subjects
Renli Teng et al.
DRUG METABOLISM AND DISPOSITION (2010)
The PLATO trial: do you believe in magic?
Victor L. Serebruany et al.
EUROPEAN HEART JOURNAL (2010)
Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial
Stefan James et al.
EUROPEAN HEART JOURNAL (2010)
Guidelines on myocardial revascularization The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)
William Wijns et al.
EUROPEAN HEART JOURNAL (2010)
Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects
Renli Teng et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI A Meta-analysis
Jessica L. Mega et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Metabolism and Disposition of the Thienopyridine Antiplatelet Drugs Ticlopidine, Clopidogrel, and Prasugrel in Humans
Nagy A. Farid et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Pharmacokinetics and Pharmacodynamics of a Bolus and Infusion of Cangrelor: A Direct, Parenteral P2Y12 Receptor Antagonist
Wendell S. Akers et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
A Risk Score to Predict Bleeding in Patients With Acute Coronary Syndromes
Roxana Mehran et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate
Laurent Bonello et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P450 2C19*2 Loss-of-Function Allele or Proton Pump Inhibitor Coadministration A Systematic Meta-Analysis
Jean-Sebastien Hulot et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA Boxed Warning A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association
David R. Holmes et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents
Neena S. Abraham et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis
Jessica L. Mega et al.
LANCET (2010)
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial
Lars Wallentin et al.
LANCET (2010)
Clopidogrel with or without Omeprazole in Coronary Artery Disease.
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Smoking at least 10 cigarettes per day increases platelet inhibition by clopidogrel in patients with ST-segment-elevation myocardial infarction
Young-Hoon Jeong et al.
THROMBOSIS RESEARCH (2010)
Advances in Antiplatelet Therapy: Agents in Clinical Development
Dominick J. Angiolillo et al.
AMERICAN JOURNAL OF CARDIOLOGY (2009)
Ticagrelor: The First Reversibly Binding Oral P2Y(12) Receptor Antagonist
Steen Husted et al.
CARDIOVASCULAR THERAPEUTICS (2009)
2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update) A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Frederick G. Kushner et al.
CIRCULATION (2009)
Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease The ONSET/OFFSET Study
Paul A. Gurbel et al.
CIRCULATION (2009)
Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes
Jessica L. Mega et al.
CIRCULATION (2009)
P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use
Lars Wallentin
EUROPEAN HEART JOURNAL (2009)
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease
Christoph Varenhorst et al.
EUROPEAN HEART JOURNAL (2009)
Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy
Alan R. Shuldiner et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Population Pharmacokinetic Analyses to Evaluate the Influence of Intrinsic and Extrinsic Factors on Exposure of Prasugrel Active Metabolite in TRITON-TIMI 38
Rebecca E. Wrishko et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease
D. S. Small et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2009)
2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update) A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Frederick G. Kushner et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
The Efficacy and Safety of Prasugrel With and Without a Glycoprotein IIb/IIIa Inhibitor in Patients With Acute Coronary Syndromes Undergoing Percutaneous Intervention A TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) Analysis
Michelle O'Donoghue et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome
C. Frere et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
Studies on the role of the extracellular cysteines and oligomeric structures of the P2Y(12) receptor when interacting with antagonists
Z. Ding et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
Clopidogrel attenuates atheroma formation and induces a stable plaque phenotype in apolipoprotein E knockout mice
Arnon Afek et al.
MICROVASCULAR RESEARCH (2009)
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials
Michelle L. O'Donoghue et al.
LANCET (2009)
Intravenous Platelet Blockade with Cangrelor during PCI.
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Cytochrome P-450 Polymorphisms and Response to Clopidogrel.
Jessica L. Mega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Lars Wallentin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Platelet Inhibition with Cangrelor in Patients Undergoing PCI.
Robert A. Harrington et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Genetic Determinants of Response to Clopidogrel and Cardiovascular Events.
Tabassome Simon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Anti-platelet drugs and outcome in severe infection: Clinical impact and underlying mechanisms
Johannes Winning et al.
PLATELETS (2009)
Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3
Robert F. Storey et al.
PLATELETS (2009)
Strategy for the Treatment of Clopidogrel Low Responsiveness in Diabetes Mellitus and Stent Implantation
Jang-Young Kim
Korean Circulation Journal (2009)
Pharmacology of emerging novel platelet inhibitors
Dominick J. Angiolillo et al.
AMERICAN HEART JOURNAL (2008)
Clinical profile of prasugrel, a novel thienopyridine
Dominick J. Angiolillo et al.
AMERICAN HEART JOURNAL (2008)
The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: Results from the Clopidogrel for the Reduction of Events During Observation (CREDO) Trial
Patricia J. M. Best et al.
AMERICAN HEART JOURNAL (2008)
Acute coronary syndromes and diabetes mellitus - A winning ticket for prasugrel
Valentin Fuster et al.
CIRCULATION (2008)
Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38
Stephen D. Wiviott et al.
CIRCULATION (2008)
Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel
David S. Small et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease
C. Steven Ernest et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2008)
Clopidogrel resistance - More grist for the mill
John A. Cairns et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Calcium-Channel Blockers Reduce the Antiplatelet Effect of Clopidogrel
Jolanta M. Siller-Matula et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Chronic kidney disease increases risk for venous thromboembolism
Keattiyoat Wattanakit et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)
Interaction of the active metabolite of prasugrel, R-138727, with cysteine 97 and cysteine 175 of the human P2Y12 receptor
I. Algaier et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
Effect of Atorvastatin on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Subjects
Nagy A. Farid et al.
PHARMACOTHERAPY (2008)
Interaction between statins and clopidogrel: is there anything clinically relevant
R. Bhindi et al.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2008)
Transitioning patients from cangrelor to clopidogrel: Pharmacodynamic evidence of a competitive effect
Steven R. Steinhubl et al.
THROMBOSIS RESEARCH (2008)
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention - The prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial
Stephen D. Wiviott et al.
CIRCULATION (2007)
Prasugrel: A novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile
Joseph A. Jakubowski et al.
CARDIOVASCULAR DRUG REVIEWS (2007)
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Stephen D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
From ATP to AZD6140:: The discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis
Brian Springthorpe et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
Predictors and impact of major Hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 trial
Frederick Feit et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
Effect of clopidogrel on the inflammatory progression of early atherosclerosis in rabbits model
Ming Li et al.
ATHEROSCLEROSIS (2007)
Diabetes and mortality following acute coronary syndromes
Sean M. Donahoe et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Purine and pyrimidine receptors
G. Burnstock
CELLULAR AND MOLECULAR LIFE SCIENCES (2007)
Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently
N. A. Farid et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Renal function and outcomes in acute coronary syndrome: impact of clopidogrel
Matyas Keltai et al.
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION (2007)
Impact of P-glycoprotein on clopidogrel absorption
Dirk Taubert et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38)
Stephen D. Wiviott et al.
AMERICAN HEART JOURNAL (2006)
Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor:: A single ascending dose study in healthy humans
Fumitoshi Asai et al.
PLATELETS (2006)
Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450
JLF Rehmel et al.
DRUG METABOLISM AND DISPOSITION (2006)
Platelet adhesion via glycoprotein IIb integrin is critical for atheroprogression and focal cerebral ischemia -: An in vivo study in mice lacking glycoprotein IIb
S Massberg et al.
CIRCULATION (2005)
Preclinical and clinical studies with selective reversible direct P2Y12 antagonists
JJJ van Giezen et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2005)
Pharmacology of CS-747 (Prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity
Y Niitsu et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2005)
Pyridine nucleotides and calcium signalling in arterial smooth muscle: from cell physiology to pharmacology
AM Evans et al.
PHARMACOLOGY & THERAPEUTICS (2005)
Intravenous adenosine and dyspnea in humans
NK Burki et al.
JOURNAL OF APPLIED PHYSIOLOGY (2005)
Neointimal smooth muscle cells display a proinflammatory phenotype resulting in increased leukocyte recruitment mediated by P-selectin and chemokines
U Zeiffer et al.
CIRCULATION RESEARCH (2004)
Phosphoinositide 3-kinases and the regulation of platelet function
SP Jackson et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2004)
Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction
NS Anavekar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Synergistic action between inhibition of P2Y12/P2Y1 and P2Y12/thrombin in ADP- and thrombin-induced human platelet activation
S Nylander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2004)
Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome
ZH Xiao et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
Identification of the active metabolite of ticlopidine from rat in vitro meta bolites
K Yoneda et al.
BRITISH JOURNAL OF PHARMACOLOGY (2004)
ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels
AK Wihlborg et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
Emerging roles for P2X1 receptors in platelet activation
MP Mahaut-Smith et al.
PLATELETS (2004)
Scientific and therapeutic insights into the role of the platelet P2Y12 receptor in thrombosis
PB Conley et al.
CURRENT OPINION IN HEMATOLOGY (2003)
Clopidogrel for coronary stenting - Response variability, drug resistance, and the effect of pretreatment platelet reactivity
PA Gurbel et al.
CIRCULATION (2003)
Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease
U Klinkhardt et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease
RF Storey et al.
PLATELETS (2002)
A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation
S Massberg et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Changes in platelet P-selectin and in plasma C-reactive protein in acute atherosclerotic ischemic stroke treated with a loading dose of clopidogrel
JK Cha et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2002)
The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions
PJM Best et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2002)
P2 receptors: new potential players in atherosclerosis
F Di Virgilio et al.
BRITISH JOURNAL OF PHARMACOLOGY (2002)
Purinergic signaling and vascular cell proliferation and death
G Burnstock
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2002)
Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein
DP Chew et al.
AMERICAN JOURNAL OF CARDIOLOGY (2001)
The P2Y12 receptor induces platelet aggregation through weak activation of the αIIbβ3 integrin -: a phosphoinositide 3-kinase-dependent mechanism
G Kauffenstein et al.
FEBS LETTERS (2001)
Platelet CD40 ligand (CD40L) -: subcellular localization, regulation of expression, and inhibition by clopidogrel
A Hermann et al.
PLATELETS (2001)
Identification of the platelet ADP receptor targeted by antithrombotic drugs
G Hollopeter et al.
NATURE (2001)
Platelets from a patient heterozygous for the defect of P2CYC receptors for ADP have a secretion defect despite normal thromboxane A2 production and normal granule stores -: Further evidence that some cases of platelet 'primary secretion defect' are heterozygous for a defect of P2CYC receptors
M Cattaneo et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2000)
The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties
A Sugidachi et al.
BRITISH JOURNAL OF PHARMACOLOGY (2000)
分享论文
